Neuroblastoma is the most common extracranial solid tumor of childhood, with a median age at diagnosis of approximately 17 months.1 The tumor derives from primitive sympathetic nervous system tissue2 and thus typically arises in the adrenal glands or in sympathetic ganglia.

Variation in hospital admission of sickle cell patients from the emergency department using the Pediatric Health Information System. Late effects included leukemia or myelodysplastic syndrome in 3 patients (8%) and 1 case of thyroid carcinoma. Retrospective studies revealed the high survival rate of 12–18 month old age group, previously categorized as high-risk, and prompted the decision to reclassify 12–18 month old children without N-myc (also commonly referred to as MYCN) amplification to intermediate risk category.[33]. Several other studies have addressed survival after relapse or progression. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Factors investigated have included occupation (i.e. [24] As mIBG is not always taken up by neuroblastomas, researchers have explored in children with neuroblastoma whether another type of nuclear imaging, fluoro-deoxy-glucose - positron emission tomography, often termed "F-FDG-PET", might be useful. MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders. For the overall cohort, median OS was 16.1 ± 4.3 months, 1‐year OS was 50.9 ± 6.5 months, and 2‐year OS was 41.8 ± 6.8 months. Data were compiled from three phase II trials of temozolomide, topotecan–vincristine–doxorubicin (TVD) and topotecan–temozolomide (TOTEM),6-8 and included 88 patients with neuroblastoma. Despite the limitations of historical controls, for a rare disease such as neuroblastoma, there may be situations in which this is a reasonable study design with which to identify agents that warrant further investigation. The PH assumption was not violated for any factors. Stage L1: Localized disease without image-defined risk factors.
Patients were on study for a median of 3.5 months (interquartile range [IQR] 1.9–6.2). The TVD regimen is incorporated to the SIOPEN frontline trial (NCT01704716) for all patients who do not achieve a complete metastatic response with induction chemotherapy. In 19 cases where details about the timing of the response were available, 14 (73.7%) had a response after two cycles. The multikinase inhibitor RXDX-105 is effective against neuroblastoma. Biology of Blood and Marrow Transplantation. A prognostic nomogram for neuroblastoma in children. One patient received subsequent treatment on New Approaches to Neuroblastoma Therapy consortium (NANT) protocol 0701 (ClinicalTrials.gov NCT00659984) with no carrier‐added 131I‐MIBG. Figure 1 shows a CONSORT diagram for this study. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Acute lymphoblastic leukemia clonal distribution between bone marrow and peripheral blood.

Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK. Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma. Supported by National Institutes of Health grants U10 CA180899 and U10 CA98413 (Children's Oncology Group Statistics and Data Center); U10 CA98543 (Children's Oncology Group Chair's Grant); and U10 CA01015, U10 CA07502, and U10 CA12502 (Children's Oncology Group Phase 1/Pilot Consortium). [65] ArrayCGH, FISH, or conventional cytogenetics cannot detect copy neutral LOH. Therefore, it is possible to use the PFS and TTP results of the current study as historical context when designing future trials of antitumor agents. The aim of this study is to provide pooled data on clinical outcomes (progression‐free survival [PFS], response rate, clinical benefit ratio, duration of response) of children with refractory and relapsed neuroblastomas treated in phase II clinical trials within ITCC and SIOPEN consortia. Most importantly, the team hope to identify the new genetic changes associated with relapse, to help develop new drugs for children with relapsed neuroblastoma. Use the link below to share a full-text version of this article with your friends and colleagues. In the absence of clinical symptoms, the more frequently that assessments of disease burden are performed, the sooner disease recurrence/progression can be identified.